Zura Bio Ltd reports results for the quarter ended June 30 - Earnings Summary

Zura Bio

12/08/2026 14:31

Zura Bio Ltd ZURA.OQ reported a quarterly adjusted loss of 21 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -17 cents.  The mean expectation of eight analysts for the quarter was for a loss of 20 cents per share. Wall Street expected results to range from -21 cents to -19 cents per share.
Reported revenue was zero​; analysts expected zero. 
Zura Bio Ltd's reported EPS for the quarter was a loss of 21 cents​.
The company reported a quarterly loss of $26.3 million.
Zura Bio Ltd shares had fallen by 5.8% this quarter and gained 6.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 3.8% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for Zura Bio Ltd is $19.00, about 70.7% above its last closing price of $5.56
This summary was machine generated from LSEG data August 12 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.20
-0.21
Missed
Mar. 31 2026 
-0.17
-0.22
Missed
Dec. 31 2025 
-0.20
-0.49
Missed
Sep. 30 2025 
-0.18
-0.21
Missed